Related Experiment Video
Updated: Jun 15, 2026
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Clinical approaches to preserve beta-cell function in diabetes
1Endocrine Service and Diabetes and Heart Center of the Heart Institute, Hospital das, Clinicas of The University of São Paulo Medical School, São Paulo, SP 05403-000, Brazil. bernarwaj@globo.com
Advances in Experimental Medicine and Biology
|March 11, 2010
Summary
Type 2 diabetes involves progressive beta-cell loss. Treatments like GLP-1 receptor agonists and DPP-4 inhibitors help preserve beta-cell function and mass, improving glucose homeostasis.
Area of Science:
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes (DM2) is characterized by progressive decline in pancreatic beta-cell function and mass.
- At diagnosis, islet function is approximately 50% of normal, with significant beta-cell mass reduction due to accelerated apoptosis.
Purpose of the Study:
- To review interventions aimed at preserving beta-cell function and mass in type 2 diabetes.
- To highlight the role of incretin-based therapies in managing DM2.
Main Methods:
- Review of existing literature on type 2 diabetes pathophysiology and treatment strategies.
- Focus on interventions impacting beta-cell secretion and survival, including incretin hormone pathways.
Main Results:
- Short-term improvements in beta-cell secretion are achieved with weight loss, metformin, sulfonylureas, and insulin.
- Long-term beta-cell preservation is demonstrated with intensive insulin therapy, antiapoptotic drugs (glitazones), and glucagon-like peptide-1 receptor agonists (GLP-1 mimetics) or enhancers.
Conclusions:
- Incretin hormones, particularly GLP-1, play a crucial role in glucose homeostasis.
- GLP-1 mimetics (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin, vildagliptin) are approved and effective treatments for type 2 diabetes, preserving beta-cell function.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...